NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Links:
Two-Year Efficacy and Safety Outcomes with JAKi Treatment in Patients with Gian…
https://buff.ly/9yUSBWu
Dec-29-2025
